Fortress Biotech, Inc. (FBIO)
NASDAQ: FBIO · Real-Time Price · USD
2.830
+0.080 (2.91%)
At close: Dec 5, 2025, 4:00 PM EST
2.840
+0.010 (0.35%)
After-hours: Dec 5, 2025, 7:29 PM EST
Fortress Biotech Employees
Fortress Biotech had 101 employees as of December 31, 2024. The number of employees decreased by 85 or -45.70% compared to the previous year.
Employees
101
Change (1Y)
-85
Growth (1Y)
-45.70%
Revenue / Employee
$616,861
Profits / Employee
-$52,832
Market Cap
87.84M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
FBIO News
- 22 days ago - Fortress Biotech Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights - GlobeNewsWire
- 23 days ago - Fortress Biotech, Inc. (FBIO) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 23 days ago - Journey Medical Corporation Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights - GlobeNewsWire
- 4 weeks ago - Avenue Therapeutics Announces Acquisition of Subsidiary Baergic Bio by Axsome Therapeutics - GlobeNewsWire
- 4 weeks ago - Journey Medical Corporation to Announce Third Quarter 2025 Financial Results on November 12, 2025 - GlobeNewsWire
- 6 weeks ago - Journey Medical Corporation Reports Combined Emrosi™ (DFD-29) Phase 3 Clinical Trial Efficacy Data Analysis Presented at the 2025 Fall Clinical Dermatology Conference - GlobeNewsWire
- 6 weeks ago - Fortress Biotech and Subsidiary Urica Therapeutics Announce First Patients Dosed in Crystalys Therapeutics' Global Phase 3 Trials of Dotinurad for the Treatment of Gout - GlobeNewsWire
- 2 months ago - Journey Medical Corporation to Participate in October 2025 Investor Conferences - GlobeNewsWire